Zhang JQ, Wu YH, Qi XS. Current evidence regarding terlipressin for treatment of hepatorenal syndrome.
Shijie Huaren Xiaohua Zazhi 2019;
27:1-5. [DOI:
10.11569/wcjd.v27.i1.1]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Hepatorenal syndrome (HRS) is a serious complication of liver cirrhosis, which is characterized by oliguria, severe urinary sodium retention, and elevated serum creatinine levels. Liver transplantation is the best choice of therapy, but is rarely available. Current mainstay pharmacological therapy is vasoconstrictors with albumin. Terlipressin is a synthetic analog of vasopressin, and it has been used for the treatment of HRS. This article reviews the current status regarding terlipressin in the management of HRS from the perspective of evidence-based medicine.
Collapse